ClinicalTrials.gg
RecruitingNCT07558915Updated Nov 9, 2026

A Study to Evaluate RO7851624 in Participants With Relapsed/Refractory Multiple Myeloma (RRMM)

A Phase 1 interventional study of RO7851624 in Relapsed/Refractory Multiple Myeloma, sponsored by Genentech, Inc.. Recruiting at 2 sites in 2 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-09.

Sponsored by Genentech, Inc. (part of Hoffmann-La Roche) · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Started Jun 2026; still recruiting 4 months later.
Updated Nov 9, 2026First site in South Korea1 site addedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
160
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-18

Among 30 studies in Multiple Myeloma by Hoffmann-La Roche — 6 open to participants now, 12 under way, 1 of them phase 3. Multiple Myeloma · Hoffmann-La Roche.

Planned enrollment
9th of 29
160 · median 90
Started
2026
with 3 others
Phase 1
18 of 30
3 open now
Primary completion
2030-07
later than 10 of 11 live
Registered
29th of 30
by date

Among the 30 studies in Multiple Myeloma by Hoffmann-La Roche, this one is the 9th largest by planned enrollment of the 29 interventional ones that give a count, is one of 4 that started in 2026, is one of 18 in phase 1, reaches primary completion later than 10 of the 11 other live ones, and was the 29th registered.

Multiple Myeloma

3,763 studies on the registry are indexed under Multiple Myeloma; 768 are open to participants now.

Browse Multiple Myeloma studies →

Open to participants now

6 of the 30 studies in Multiple Myeloma by Hoffmann-La Roche are open now, in 12 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 6 open studies →

Who these studies take

Of the 584 Multiple Myeloma studies recruiting now, 429 (73%) set no upper age limit and 106 (18%) stop at 75 or younger; 36 take children under 18; 24 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 30 studies in Multiple Myeloma by Hoffmann-La Roche, or all of them as a file.
02

Study summary

This study will evaluate safety, pharmacokinetics (PK), clinical activity and pharmacodynamics (PD) of RO7851624 in participants with RRMM who are triple-class exposed (treated with proteasome inhibitors [PIs], immunomodulators [IMiDs], and anti-cluster of differentiation 38 [anti-CD38] monoclonal antibodies), and have limited remaining standard treatment options due to refractoriness, intolerance, or multiple prior therapies.

03

Conditions studied

  • Relapsed/Refractory Multiple Myeloma

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • (ECOG) Performance Status of 0 or 1.
  • of at least 12 weeks.
  • Diagnosis of multiple myeloma per International Myeloma Working Group (IMWG) criteria.
  • .

Exclusion criteria

Exclusion Criteria:

  • Treatment with any chemotherapeutic agent, or treatment with any other anti-cancer agent ( or otherwise) with insufficient prior to first dose of study treatment.
  • stem cell transplant (SCT) with insufficient time prior to first dose of study treatment.
  • Prior allogeneic SCT.
  • Prior solid organ transplantation.
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Washout period

A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
160 participants (estimated)

Study arms

  • Experimental
    RO7851624

    Participants will receive RO7851624 in a dose escalation stage followed by a dose expansion stage.

    Drug: RO7851624

Interventions

  • DrugRO7851624

    Participants will receive RO7851624 as per the schedule described in the protocol.

06

What researchers measure

Primary outcomes

  1. Percentage of Participants With Adverse Events (AEs)

    Time frame: Up to approximately 2 years

Secondary outcomes

  1. Serum Concentration of RO7851624

    Time frame: Up to approximately 2 years

  2. Objective Response Rate (ORR)

    Time frame: Up to approximately 2 years

  3. Complete Response (CR) Rate/ Stringent Complete Response (sCR) Rate)

    Time frame: Up to approximately 2 years

  4. Rate of Very Good Partial Response (VGPR) Rate or Better

    Time frame: Up to approximately 2 years

  5. Progression-Free Survival (PFS)

    Time frame: Up to approximately 2 years

  6. Duration of Response (DOR)

    Time frame: Up to approximately 2 years

  7. Time to First Response

    Time frame: Up to approximately 2 years

  8. Time to Best Response

    Time frame: Up to approximately 2 years

  9. Percentage of Participants With Anti-Drug Antibodies (ADAs) Against RO7851624 at Baseline and During the Study

    Time frame: Baseline, up to approximately 2 years

  10. Recommended Dose and Regimen of RO7851624

    Time frame: Up to approximately 2 years

07

Study locations

2 of 2 sites recruiting
08

References and documents

09

Timeline

2 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jun 2026 (actual). Primary completion is estimated for Jul 2030, 48 months after the start.

Of 212 industry-sponsored phase 1 interventional studies under Multiple Myeloma, half reached primary completion within 43 months of starting (the median), counting those still running; a quarter within 27 and three quarters within 71. This study's planned 48 months is above that.

Counting every sponsor, half of 413 studies reached it within 50 months; a quarter within 33 and three quarters within 75.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 24, 2026
First posted
Apr 30, 2026
StartActual
Jun 23, 2026
Primary completionEst.
Jul 1, 2030
CompletionEst.
Oct 1, 2031
Last update
Nov 9, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
1 site added — first site in South Korea
Show site
  • Samsung Medical Center · Gangnam-gu, South Korea
Nov 9, 2026
Show all 2 updates
  1. Nov 9, 2026
    1 site added — first site in South Korea
    Show site
    • Samsung Medical Center · Gangnam-gu, South Korea
    + 1 other change: verification date
  2. Oct 9, 2026
    Minor edits only
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07558915
Lead sponsor
Genentech, Inc.
Responsible party
Sponsor
First posted
Apr 30, 2026
Start date
Jun 23, 2026
Primary completion
Jul 1, 2030 (estimated)
Completion
Oct 1, 2031 (estimated)
Last update
Nov 9, 2026

Study contacts

Reference Study ID Number: GO46140 https://forpatients.roche.com/ No attachments to email below.
Contact
global-roche-genentech-trials@gene.com
888-662-6728 (U.S. and Canada)
Fastest response: use the inquiry form. https://www.gene.com/contact-us/submit-medical-inquiry
Contact
Clinical Trials
study director · Hoffmann-La Roche

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion